KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDivestmentsDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShares RepurchasedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVS) Asset Writedowns and Impairment (2009 - 2023)

Novartis Ag recorded quarterly Asset Writedowns and Impairment of -$940.0 million in Q2 2023, down 252.06% quarter-over-quarter from -$267.0 million in Q2 2022, and down 252.06% year-over-year from $618.2 million in Q2 2022.

Novartis Ag's Asset Writedowns and Impairment history runs 6 years deep, the most recent figure standing at -$940.0 million for Q2 2023.

  • In Q2 2023, Asset Writedowns and Impairment fell 252.06% year-over-year to -$940.0 million; the TTM figure through Jun 2023 stood at -$940.0 million (down 252.06% YoY), while the FY2009 annual figure was -$26.0, changed N/A from the prior year.
  • Asset Writedowns and Impairment came in at -$940.0 million for Q2 2023 at Novartis Ag, down from -$267.0 million in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of -$267.0 million in Q2 2022 to a low of -$940.0 million in Q2 2023.
  • A 4-year average of -$511.8 million and a median of -$420.0 million in 2020 frame the typical range for Asset Writedowns and Impairment.
  • Across the five-year window, Asset Writedowns and Impairment soared 47.55% in 2021 and sank 252.06% in 2023, its largest moves.
  • Novartis Ag's Asset Writedowns and Impairment stood at -$551.0 million in 2020, then surged by 47.55% to -$289.0 million in 2021, then increased by 7.61% to -$267.0 million in 2022, then tumbled by 252.06% to -$940.0 million in 2023.
  • According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered -$940.0 million, -$267.0 million, and -$289.0 million for Q2 2023, Q2 2022, and Q2 2021 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn
10 Gsk 88.34 Bn 83.66 Bn -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2023 -940.00 Mn
Jun 30, 2023 -940.00 Mn
Jun 30, 2022 -267.00 Mn
Jun 30, 2022 -267.00 Mn
Jun 30, 2021 -289.00 Mn
Jun 30, 2021 -289.00 Mn
Jun 30, 2020 -551.00 Mn
Jun 30, 2020 -551.00 Mn
Jun 30, 2010 82.00
Jun 30, 2010 82.00
Mar 31, 2010 65.00
Mar 31, 2010 65.00
Dec 31, 2009 -26.00
Dec 31, 2009 -26.00
Jun 30, 2009 -11.00
Jun 30, 2009 -11.00
Mar 31, 2009 16.00
Mar 31, 2009 16.00